References
- Feeny D. Diffusion of new health care technologies. Health Care Technology: Effectiveness, Efficiency, and Public Policy. Feeny D, Guyatt G, Tugwell P (Eds). Institute for Research on Public Policy, Montreal, Canada, 24–40 (1986).
- Rogers EM. Diffusion of Innovations (4th Edition). Free Press, NY, USA (1995).
- Culyer AJ. Involving stakeholders in healthcare decisions – the experience of the National Institute for Health and Clinical Excellence (NICE) in England and Wales. Healthc. Q.8(3), 56–60 (2005).
- Lenaghan J. Involving the public in rationing decisions. The experience of citizens juries. Health Policy49(1–2), 45–61 (1999).
- Abelson J, Eyles J, McLeod CB, Collins P, McMullan C, Forest PG. Does deliberation make a difference? Results from a citizens panel study of health goals priority setting. Health Policy66(1), 95–106 (2003).
- Oliver SR, Rees RW, Clarke-Jones L et al. A multidimensional conceptual framework for analysing public involvement in health services research. Health Expect11(1), 72–84 (2008).
- Abelson J, Forest PG, Eyles J, Casebeer A, Martin E, Mackean G. Examining the role of context in the implementation of a deliberative public participation experiment: results from a Canadian comparative study. Soc. Sci. Med.64(10), 2115–2128 (2007).
- Nutt PC. How decision makers evaluate alternatives and the influence of complexity. Manage. Sci.44(8), 1148–1166 (1998).
- Gauvin FP, Abelson J, Giacomini M, Eyles J, Lavis JN. ‘It all depends’: conceptualizing public involvement in the context of health technology assessment agencies. Soc. Sci. Med.70(10), 1518–1526 (2010).
- Facey K, Boivin A, Gracia J et al. Patients’ perspectives in health technology assessment: a route to robust evidence and fair deliberation. Int. J. Technol. Assess. Health Care26(3), 334–340 (2010).
- Coulter A. Perspectives on health technology assessment: response from the patient’s perspective. Int. J. Technol. Assess. Health Care20(1), 92–96 (2004).
- Noorani HZ, Husereau DR, Boudreau R, Skidmore B. Priority setting for health technology assessments: a systematic review of current practical approaches. Int. J. Technol. Assess. Health Care23(3), 310–315 (2007).
- Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int. J. Technol. Assess. Health Care23(1), 30–35 (2007).
- Pivik J, Rode E, Ward C. A consumer involvement model for health technology assessment in Canada. Health Policy69(2), 253–268 (2004).
- Wait S, Nolte E. Public involvement policies in health: exploring their conceptual basis. Health Econ. Policy Law1(Pt 2), 149–162 (2006).
- Chalkidou K, Tunis S, Lopert R et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q87(2), 339–367 (2009).
- Street JM, Braunack-Mayer AJ, Facey K, Ashcroft RE, Hiller JE. Virtual community consultation? Using the literature and weblogs to link community perspectives and health technology assessment. Health Expect.11(2), 189–200 (2008).
- Chafe R, Merali F, Laupacis A, Levinson W, Martin D. Does the public think it is reasonable to wait for more evidence before funding innovative health technologies? The case of PET scanning in Ontario. Int. J. Technol. Assess. Health Care26(2), 192–197 (2010).
- Bilimoria NM. CMS ‘never events’ and other new trends in quality health care standards for hospitals. Health Care Law Mon.2008(12), 2–10 (2008).
- Hailey D, Nordwall M. Survey on the involvement of consumers in health technology assessment programs. Int. J. Technol. Assess. Health Care22(4), 497–499 (2006).
- Fattal J, Lehoux P. Health technology assessment use and dissemination by patient and consumer groups: why and how? Int. J. Technol. Assess. Health Care24(4), 473–480 (2008).
- Massol J, Puech A, Boissel J-P et al. How to anticipate the assessment of the public health benefit of new medicines? Therapie62(5), 417–435 (2007).
- Roche T, Brunet V. Medical Devices Evaluation by the HAS in Order to be Reimbursed in France. Roche & Associes, Lyon, France (2009).
- Orvain J, Xerri B, Matillon Y. Overview of health technology assessment in France. Int. J. Technol. Assess. Health Care20(1), 25–34 (2004).
- Manning J, Paterson R. ‘Prioritization’: rationing health care in New Zealand. J. Law Med. Ethics33(4), 681–697 (2005).
- Garner S. How decisions on the use of medicines and medical devices are made. Pharmaceutical J.275(7364), 254–256 (2005).
- Stolk EA, de Bont A, van Halteren AR, Bijlmer RJ, Poley MJ. Role of health technology assessment in shaping the benefits package in The Netherlands. Expert Rev. Pharmacoeconomics Outcomes Res.9(1), 85–94 (2009).
- Fry ST. Nancy Cruzan is allowed to die, but uncertainties remain. Nurs. Outlook39(2), 96 (1991).
- Berg M, van der Grinten T, Klazinga N. Technology assessment, priority setting, and appropriate care in Dutch health care. Int. J. Technol. Assess. Health Care20(1), 35–43 (2004).
- Chalkidou K. Comparative effectiveness review within the U.K.’s National Institute for Health and Clinical Excellence. Issue Brief (Commonw. Fund)59, 1–12 (2009).
- Abelson J, Giacomini M, Lehoux P, Gauvin FP. Bringing ‘the public’ into health technology assessment and coverage policy decisions: from principles to practice. Health Policy82(1), 37–50 (2007).
- Borowski HZ, Brehaut J, Hailey D. Linking evidence from health technology assessments to policy and decision making: the Alberta model. Int. J. Technol. Assess. Health Care23(2), 155–161 (2007).
- Levin L, Goeree R, Sikich N et al. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience. Int. J. Technol. Assess. Health Care23(3), 299–309 (2007).
Websites
- Handbook on HTA capacity building. EUnetHTA work package 8. Barcelona (Spain): Catalan Agency for Health Technology Assessment and Research/European Network for Health Technology Assessment www.gencat.cat/salut/depsan/units/aatrm/pdf/eunethta_wp8_hb_hta_capacity_building.pdf
- Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Australian Government. Department of Health and Ageing www.health.gov.au/internet/main/publishing.nsf/Content/pbacguidelines-index
- Guidelines for the economic evaluation of health technologies: Canada www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf
- Arnstein SR. A ladder of citizen participation http://lithgow-schmidt.dk/sherry-arnstein/ladder-of-citizen-participation.html#d0e24
- Health technology assessment handbook 2007. Health Technology Assessment www.sst.dk/publ/Publ2008/MTV/Metode/HTA_Handbook_net_final.pdf
- Alberta: Institute of Health Economics. Consumer involvement in health technology assessment www.ihe.ca/documents/HTA-FR21.pdf
- Enhancing consumer involvement in medicines health technology assessment. Final report. Deloitte www.deloitte.com/assets/Dcom-Australia/Local%20Assets/Documents/Industries/Deloitte_Consumer%20Involvement%20in%20HTA%20Report.pdf
- Wong-Rieger D, Fowler E. Engaging patients in HTA in Canada: what’s working and what needs to be done? www.cadth.ca/media/symp-2009/presentations/CS-3/Durhane%20Wong-Reiger%20-%20Engaging%20Patients%20in%20HTA%20in%20Canada.pdf
- ISPOR global health care systems road map: Australia – health policy decision process www.ispor.org/HTARoadMaps/AustraliaHP.asp
- Morgan SG, McMahon M, Mitton C et al. Centralized drug review processes in Australia, Canada, New Zealand and the United Kingdom http://content.healthaffairs.org/cgi/content/abstract/25/2/337
- About the PBS. PBS – how do drugs get on the scheme? www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pbs-phbenbir.htm
- Advisory Committee on Prescription Medicines www.tga.gov.au/committee/acpm.htm
- Part 1: role of the PBAC. In: 1995 guidelines for the pharmaceutical industry www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pubs-guidelines-part1.htm#role
- Pharmaceutical Benefits Advisory Committee: PBAC membership www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-listing-committee3.htm
- Haas M, Viney R, Gallego G. Implementing guidelines for reimbursement in Australia: how the PBAC & MSAC use comparative cost–effectiveness www.hpm.org/Downloads/Symposium_Krakau/Marion_Haas_Australia.pdf
- Current MSAC membership www.msac.gov.au/internet/msac/publishing.nsf/content/current-membership-1
- Consumers Health Forum of Australia. Information paper: new health technologies, medical devices and prostheses www.chf.org.au/pdfs/cns/cns-462-new-health-technologies.pdf
- Review of health technology assessment in Australia: a discussion paper www.health.gov.au/internet/main/publishing.nsf/Content/208F913CD40AD7F9CA2575850080CACD/$File/htadiscussionpaper.pdf
- Funding for new medical technologies and procedures: application and assessment guidelines www.health.gov.au/internet/msac/publishing.nsf/Content/D81BE529B98B3DB6CA2575AD0082FD1B/$File/guidelines.pdf
- Medical Services Advisory Committee performance report 2008–2009. Canberra: Medical Services Advisory Committee www.health.gov.au/internet/msac/publishing.nsf/Content/9FD4C2646B76FA43CA25768F00221A26/$File/MSAC_Performance%20_Report_2008-09.pdf
- Are you involved with new technologies or clinical procedures? Are they, or should they be funded under Medicare? Consider an MSAC assessment www.health.gov.au/internet/msac/publishing.nsf/Content/61DB23F245AFC9C8CA2575AD0082FCA0/$File/Brochure_MSAC_Final_160606.pdf
- Healy P, Pugatch M. Theory versus practice: discussing the governance of health technology assessment systems www.stockholm-network.org/downloads/publications/Theory_versus_Practice.pdf
- Health Technology Assessment of Medical Devices (2006). Medical Devices Canada http://web.archive.org/web/20060620202547/medec.org/docs/HTA-english.pdf
- Procedure for Common Drug Review www.cadth.ca/media/cdr/process/CDR_Procedure_e.pdf
- Rochaix L, Xerri B. National Authority for Health: France www.commonwealthfund.org/Content/Publications/Issue-Briefs/2009/Jul/National-Authority-for-Health-France.aspx
- Chicoye A, Chhabra A. ISPOR global health care systems road map: France – pharmaceuticals www.ispor.org/htaroadmaps/France.asp
- Chicoye A, Levesque K. ISPOR global health care systems road map: France – medical devices. www.ispor.org/htaroadmaps/FranceMD.asp
- Medical device assessment in France: guidebook. Haute Autorite de Sante (HAS) www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/guide_dm_gb_050310.pdf
- Rapid assessment method for assessing medical and surgical procedures. Cedex (France) www.has-sante.fr/portail/upload/docs/application/pdf/rapid_assessment_method_eval_actes.pdf
- Nguyen-Kim L, Or Z, Paris V, Sermet C. The politics of drug reimbursement in England, France and Germany www.irdes.fr/EspaceAnglais/Publications/IrdesPublications/QES099.pdf
- General method for assessing health technologies www.has-sante.fr/portail/upload/docs/application/pdf/general_method_eval_techno.pdf
- Haute Autorite de Sante www.has-sante.fr
- EuroPharma Today: French price cuts continue, but austerity budget could be worse www.europharmatoday.com/2010/10/french-price-cuts-continue-but-austerity-budget-could-be-worse.html
- Sorenson C. The role of HTA in coverage and pricing decisions: a cross-country comparison. Euro Observer: the Health Policy Bulletin of the European Observatory on Health Systems and Policies 2009 www.euro.who.int/__data/assets/pdf_file/0019/80335/EuroObserver_spring2009.pdf
- Nasser M, Sawicki P. Institute for Quality and Efficiency in Health Care: Germany www.commonwealthfund.org/∼/media/Files/Publications/Issue%20Brief/2009/Jul/Chalkidou/1294_Nasser_CER_Germany_issue_brief_724.pdf
- Holtorf AP, Matuszewski K, Nuijten M, Vauth C. ISPOR global health care systems road map: Germany www.ispor.org/htaroadmaps/Germany.asp
- Pharmaceutical pricing and reimbursement information: Germany. Pharmaceutical Pricing and Reimbursement Information – PPRI; 2008. http://ppri.oebig.at/Downloads/Results/Germany_PPRI_2008.pdf
- The Federal Joint Committee. Berlin: Gemeinsamer Bundesausschuss, Institut fur Qualitat und Wirtschaftlichkeit in Gesundheitswesen www.g-ba.de/downloads/17–98–2804/2010–2001–01-Faltblatt-GBA_engl.pdf
- Institute for Quality and Efficiency in Health Care. Independent, patient-oriented, evidence-based www.iqwig.net/methods-procedures.926.en.html
- Decision-making about new health interventions. Wellington, NZ: National Health Committee www.nhc.health.govt.nz/moh.nsf/indexcm/nhc-new-health-interventions
- District health board decision-making about new health interventions: a background paper www.nhc.health.govt.nz/moh.nsf/pagescm/667/$File/dhb-decisions-new-health-background-paper.pdf
- PHARMAC consultation www.pharmac.govt.nz/patients/haveyoursay/consultation
- Medicines strategy. Submission on consultation document: ‘Towards a medicines strategy’. (PHARMAC) www.pharmac.govt.nz/2009/07/10/Submission%20on%20the%20development%20of%20the%20Medicines%20Strategy.pdf/text
- Guidelines for funding applications to PHARMAC 2010 www.pharmac.govt.nz/2010/02/11/Guidelines%20for%20Suppliers%20Submissions.pdf/text
- Operating policies and procedures of the Pharmaceutical Management Agency 3rd Edition www.pharmac.govt.nz/2005/12/22/231205.pdf
- ISPOR global health care systems road map: Scotland www.ispor.org/HTARoadMaps/Scotland.asp
- An evaluation of how SMC has engaged with its key stakeholders and shaped medicines use across NHS Scotland: summary report www.scottishmedicines.org.uk/files/SMC_Eval1_FINAL_lores.pdf
- Scottish Medicines Consortium www.scottishmedicines.org.uk/smc/22.html
- Facey K. Improving impact of patient participation in health technology assessment http://ecpc-online.org/component/docman/doc_download/123-karen-facey-patient-participation-in-hta.html?ItemId=127
- ISPOR global health care systems road map: The Netherlands www.ispor.org/HTARoadMaps/Netherlands.asp
- Schafer W, Kroneman M, Boerma W et al. European Observatory on Health Care Systems www.euro.who.int/en/home/projects/observatory/publications/health-system-profiles-hits/full-list-of-hits/netherlands-hit-2010
- van Nooten F, van Agthoven M. Mandatory pharmacoeconomic studies in the Dutch reimbursement setting. Institute for Medical Technology Assessment. Newsletter. 3(1), 1–3 (2005) www.imta.nl/publications/imta_newsletter_3_1.pdf
- Supporting rational local decision-making about medicines (and treatments): a handbook of good practice guidance www.npc.co.uk/policy/resources/handbook_executive.pdf
- Defining guiding principles for processes supporting local decision making about medicines. Final report. National Prescribing Centre www.midessex.nhs.uk/Documents/Key-Documents/Policies%20and%20Procedures/Medicines%20Management%20Policies%20and%20Procedures/DH%20Defining%20Guiding%20Principles%20for%20Processes%20supporting%20Local%20Decision%20Making%20about%20Medicines%20Report.pdf
- Wilson G. ISPOR global health care systems road map: United Kingdom – diagnostics. www.ispor.org/htaroadmaps/UKDiagnostics.asp
- ISPOR global health care systems road map: United Kingdom (England and Wales) – reimbursemment process www.ispor.org/htaroadmaps/UK.asp
- Guide to the single technology appraisal process. London NICE www.nice.org.uk/media/913/06/Guide_to_the_STA-proof_6-26-10-09.pdf
- ISPOR global health care systems road map: United States – health policy decision process www.ispor.org/htaroadmaps/USHP.asp
- Health technology assessment. Health technology selection process. Olympia (WA, USA) www.hta.hca.wa.gov/documents/selection_process.pdf
- Factors CMS considers in opening a National Coverage Determination www.cms.gov/mcd/ncpc_view_document.asp?id=6
- National Coverage Determinations with data collection as a condition of coverage: coverage with evidence development. In: Guidance for the Public, Industry, and CMS Staff. Baltimore (MD): U.S. Department of Health & Human Services. Centers for Medicare & Medicaid Services www.cms.gov/mcd/ncpc_view_document.asp?id=8
- Factors CMS considers in referring topics to the Medicare Evidence Development & Coverage Advisory Committee. In: Guidance for the Public, Industry, and CMS Staff. Baltimore (MD): U.S. Department of Health & Human Services. Centers for Medicare & Medicaid Services www.cms.gov/mcd/ncpc_view_document.asp?id=10
- Guiding principles for when National Coverage Determination topics are referred for external expertise via a technology assessment and/or the Medicare Coverage Advisory Committee. Draft guidance – not for implementation www.cms.gov/FACA/Downloads/guidelines.pdf
- All Wales Medicines Strategy Group: Independent review process www.wales.nhs.uk/sites3/Documents/371/Independent%20Review%20process%20_fina%20for%20website_.pdf
- All Wales Medicines Strategy Group, Vale of Glamorgan (Wales) www.wales.nhs.uk/sites3/home.cfm?orgid=371
- AHTDP information and reports. Health Technologies and Services Policy Unit www.health.alberta.ca/initiatives/AHTDP-info-reports.html#newsletter
- OHTAC recommendations. Decision-making framework www.health.gov.on.ca/english/providers/program/ohtac/decision_frame.html
- Ontario Health Technology Advisory Committee: evidence-based advice on technology to advance health www.health.gov.on.ca/english/providers/program/ohtac/ohtac_mn.html
- MAS – OHTAC process overview www.health.gov.on.ca/english/providers/program/ohtac/pdf/pe_phase_2_20071214.pdf
- Medical Technology Assessment Program www.oregon.gov/OHPPR/HRC/docs/HRC.Reports/MEDTAP_09_ accepted.pdf
- Medical Technology Assessment Program. Adopted by the Health Resources Commission pn 2-17-06 www.oregon.gov/OHPPR/HRC/docs/Policy/MedTapPolicy.pdf
- Health technology assessment – HTA. Prioritization criteria www.hta.hca.wa.gov/documents/prioritization_criteria.pdf
- Washington Health Technology Assessment Program (overview) www.hta.hca.wa.gov/documents/hta_overview.pdf
- Health technology assessment: program review www.hta.hca.wa.gov/documents/program_review.pdf